Total for the last 12 months
number of access : ?
number of downloads : ?
ID 112393
Sato, Shiho Okayama University|South Miyagi Medical Center
Zamami, Yoshito Okayama University|Tokushima University KAKEN Search Researchers
Imai, Toru Nihon University
Tanaka, Satoshi South Miyagi Medical Center
Koyama, Toshihiro Okayama University
Chuma, Masayuki Nihon University
Koga, Tadashi Shin Nippon Biomedical Laboratories, Ltd
Takechi, Kenshi Tokushima University
Kurata, Yasuko Okayama University
Kondo, Yutaka Harvard Medical School
Sendo, Toshiaki Okayama University
Nakura, Hironori Okayama University
Content Type
Journal Article
Amiodarone (AMD) and nifekalant (NIF) are used in the treatment of ventricular fibrillation or tachycardia; however, only few studies have been conducted on their efficacies. Therefore, a meta-analysis was conducted. Relevant sources were identified from PubMed, Cochrane Central Register of Controlled Trials, and Igaku Chuo Zasshi. The outcomes were short-term and long-term survival in patients with shock-resistant ventricular fibrillation /pulseless ventricular tachycardia. Thirty-three studies were analysed. The results showed that, compared to the control treatment, AMD did not improve short-term survival (odds ratio (OR): 1.25, 95% confidence interval (CI): 0.91–1.71) or long-term survival (OR: 1.00, 95% CI: 0.63–1.57). However, compared to the control treatment, NIF significantly improved short-term survival (OR: 3.23, 95% CI: 2.21–4.72) and long-term survival (OR: 1.88, 95% CI: 1.36–2.59). No significant difference was observed in short-term survival (OR: 0.85, 95% CI: 0.63–1.15) or long-term survival (OR: 1.25, 95% CI: 0.67–2.31) between AMD- and NIF-treated patients. The results suggest that NIF is beneficial for short-term and long-term survival in shock-resistant ventricular fibrillation/pulseless ventricular tachycardia; however, the efficacy of AMD in either outcome is not clear.
Journal Title
Scientific Reports
Springer Nature
Start Page
Published Date
Supplementary Table : srep_7_12683_s1.doc
© The Author(s) 2017
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit
DOI (Published Version)
URL ( Publisher's Version )
FullText File
Medical Sciences
University Hospital